Abstract:Abstract Introduction: Liver cancer is the second cause of cancer-related mortality worldwide. Currently, there are only two systemic agents able to increase survival in patients at advanced stages (i.e. sorafenib and regorafenib). Median survival of these patients is still poor, which highlights the need for new therapies. Our aim is to identify key regulatory gene networks with oncogenic properties amenable for therapeutic intervention through 1) integration of gene expression and DNA methylation data from human HCC samples followed by 2) functional validation in mice using shRNA screens. Methods: DNA methylation (Illumina HM450) and mRNA expression (Affymetrix human genome U219) data of 215 human HCC samples (Villanueva, Hepatology 2015) were analyzed to identify key gene regulatory networks. A causality test interrogated the impact of cis and trans regulation of promoter methylation on gene expression (Yoo, PLoS Genet 2015). A key regulator gene was defined when it regulated a substantial number of downstream genes (more than 2 standard deviations from the mean predicted trans-regulated downstream genes). Data analysis includes differential gene expression, topological overlap clustering (hierarchical, non-negative factorization [NMF]), and gene annotation. The tumorigenic potential of candidate tumor suppressors was experimentally validated through a positive selection shRNA (short-hairpin RNA) screen in mice (6 shRNAs/gene, 48 shRNAs/pool, 5 mice/library). Results: We identified 116 potential HCC key regulator genes, predicted to regulate expression of between 1,484 and 3,511 downstream genes for each one. Among the key regulators, 60 were classified as potential tumor maintenance genes and 56 as potential tumor suppressors genes based on differential expression with non-tumoral tissue (FDR<0.05). Hierarchical clustering of downstream genes showed significant overlap among multiple key regulators, suggesting their function in co-regulatory networks. Gene annotation showed a majority of key regulators associated (FDR<0.05) with focal adhesion and matrix reorganization. Three clusters of patients emerged upon NMF clustering of the key regulator’s gene expression, one of which showed (n=69/215, 32% of patients) significant overlap with the previously described CTNNB1 subclass of HCC (Chiang, Cancer Res 2008). In mice, 2/6 shRNA libraries showed significant accelerated tumor growth when compared to control [median time to 400 cc of tumor volume were 29 (library #2) and 30 (library #3) versus 39 days in control, P<0.05], suggesting enrichment of bona fide tumor suppressors. Planned sequencing analysis will confirm the identity of these candidates. Conclusions: We have identified 116 putative key regulators of hepatocarcinogenesis by integrative analysis of gene expression and DNA methylation. Functional validation indicates enrichment of bona fide tumor suppressors. Citation Format: Amanda J. Craig, Seungyeul Yoo, Verónica Miguela, Delia D'Avola, Pedro Molina-Sánchez, Josep Llovet, Amaia Lujambio, Jun Zhu, Augusto Villanueva. Integrative molecular analysis of gene expression and methylation reveals 116 putative key regulator genes of human hepatocarcinogenesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4393. doi:10.1158/1538-7445.AM2017-4393

Abstract 2950: Epigenetic Silencing BCL6B Inactivates P53 Signaling and Causes Human Hepatocellular Carcinoma Cell Resist to 5-FU

BCL6B Hypermethylation Predicts Metastasis and Poor Prognosis in Early-Stage Hepatocellular Carcinoma after Thermal Ablation

BCLB, Methylated in Hepatocellular Carcinoma, is a Starvation Stress Sensor That Induces Apoptosis and Autophagy Through the AMPK-mTOR Signaling Cascade

Epigenetic Inactivation of Bcl6b, A Novel Functional Tumour Suppressor for Gastric Cancer, is Associated with Poor Survival

Zinc Finger Protein 296 Promotes Hepatocellular Carcinoma Progression Via Intervening Interaction Between Macrophages and B Cells.

Epigenetic Silencing BCL6B Induced Colorectal Cancer Proliferation and Metastasis by Inhibiting P53 Signaling.

B Cell CLL/lymphoma 6 Member B Inhibits Hepatocellular Carcinoma Metastases in Vitro and in Mice.

BCL6B expression in hepatocellular carcinoma and its efficacy in the inhibition of liver damage and fibrogenesis.

Association of Low P16ink4a and P15ink4b Mrnas Expression with Their Cpg Islands Methylation with Human Hepatocellular Carcinogenesis

Epigenetic Identification of Ubiquitin Carboxyl-Terminal Hydrolase L1 As a Functional Tumor Suppressor and Biomarker for Hepatocellular Carcinoma and Other Digestive Tumors

CBL0137 Administration Suppresses Human Hepatocellular Carcinoma Cells Proliferation and Induces Apoptosis Associated with Multiple Cell Death Related Proteins.

BCL11B Suppresses Tumor Progression and Stem Cell Traits in Hepatocellular Carcinoma by Restoring P53 Signaling Activity

Hypermethylation of Growth Arrest DNA Damage-Inducible Gene 45 Β Promoter in Human Hepatocellular Carcinoma

Abstract 4393: Integrative Molecular Analysis of Gene Expression and Methylation Reveals 116 Putative Key Regulator Genes of Human Hepatocarcinogenesis

Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma

Aberrant Enhancer Hypomethylation Contributes to Hepatic Carcinogenesis Through Global Transcriptional Reprogramming

Promoter Hypermethylation Mediated Downregulation Of Fbp1 In Human Hepatocellular Carcinoma And Colon Cancer

SLC38A6, Regulated by EP300-mediated Modifications of H3K27ac, Promotes Cell Proliferation, Glutamine Metabolism and Mitochondrial Respiration in Hepatocellular Carcinoma

BIRC6 Promotes Hepatocellular Carcinogenesis: Interaction of BIRC6 with P53 Facilitating P53 Degradation

MYL6B, a Myosin Light Chain, Promotes MDM2-mediated P53 Degradation and Drives HCC Development

Abstract 5970: Function and Regulatory Mechanism of GPM6A in Hepatocellular Carcinoma Development and Progression